MacroGenics to Participate in Upcoming Investor Conference
08 Janeiro 2024 - 6:30PM
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company
focused on developing, manufacturing and commercializing innovative
monoclonal antibody-based therapeutics for the treatment of cancer,
today announced that the Company's management will participate in
the following upcoming investor conference:
- 42nd Annual J.P. Morgan Healthcare
Conference. MacroGenics’ President & Chief Executive
Officer, Scott Koenig, M.D., Ph.D., will provide a corporate
overview on Thursday, January 11, 2024, at 7:30 am PT. Management
will also participate in one-on-one meetings.
A webcast of the above presentation may be accessed under
"Events & Presentations" in the Investor Relations section of
MacroGenics' website at http://ir.macrogenics.com/events.cfm. The
Company will maintain an archived replay of this webcast on its
website for 30 days after the conference.
About MacroGenics, Inc. MacroGenics (the Company) is
a biopharmaceutical company focused on developing, manufacturing
and commercializing innovative monoclonal antibody-based
therapeutics for the treatment of cancer. The Company generates its
pipeline of product candidates primarily from its proprietary suite
of next-generation antibody-based technology platforms, which have
applicability across broad therapeutic domains. The combination of
MacroGenics' technology platforms and protein engineering expertise
has allowed the Company to generate promising product candidates
and enter into several strategic collaborations with global
pharmaceutical and biotechnology companies. For more information,
please see the Company's website at www.macrogenics.com.
MacroGenics and the MacroGenics logo are trademarks or registered
trademarks of MacroGenics, Inc.
###
CONTACTS:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172, info@macrogenics.com
MacroGenics (NASDAQ:MGNX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
MacroGenics (NASDAQ:MGNX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024